LONDON, UK / ACCESSWIRE / January 09, 2018 / Active-Investors.com has just released a free research report on RXi Pharmaceuticals Corp. (NASDAQ: RXII). If you want access to this report all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=RXII as the Company's latest news hit the wire. On January 05, 2018, the Company announced that it will execute a reverse stock split of its shares of common stock at a ratio of 1-for-10, becoming effective on January 08, 2018. Every ten shares of the Company's common stock will be combined into one share, thereby reducing the Company's issued and outstanding common stock from approximately 24.3 million shares to approximately 2.4 million shares. Register today and get access to over 1,000 Free Research Reports by joining our site below:
Active-Investors.com is focused on giving you timely information and the inside line on companies that matter to you. This morning, RXi Pharmaceuticals most recent news is on our radar and our team decided to put out a fantastic report on the company that is now available for free below:
The split will also proportionately adjust outstanding options issued under RXi Pharma's equity incentive plan and outstanding warrants to purchase common stock, including listed warrants trading on the Nasdaq Capital Market. The decision was approved by the Company's stockholders at the annual stockholder meeting held on June 06, 2017.
Details of Reverse Stock Split
As a result of the reverse stock split, no fractional shares of common stock will be issued. Holders of RXi Pharma's common stock will receive a cash payment instead of fractional shares to which they would otherwise be entitled. After the effective time of the reverse stock split, shareholders with shares held in certificate form will receive a Letter of Transmittal and instructions from the Company's transfer agent, Computershare, Inc. Shareholders that hold shares in book-entry form or hold their shares in brokerage accounts will see the impact of the reverse stock split reflected in their accounts.
Reason for the Decision
On August 03, 2017, the Nasdaq Stock Market granted RXi Pharma a 180-day extension to meet the listing requirements for continued listing on its exchange. The Company currently has until January 29, 2018, to regain compliance with the Nasdaq Stock Market's minimum bid price requirement, and to regain compliance, RXi Pharma's common stock must have a minimum bid price per share of at least $1.00 for 10 consecutive business days. The main reason for the reverse stock split decision is to increase the per share trading price of the Company's common stock in order to help ensure a share price high enough to satisfy the $1.00 per share minimum bid price requirement. But there can be no assurance that the reverse stock split will have the desired effect of sufficiently raising the bid price of the Company's common stock for the required period.
RXi Pharma's Last Reverse Stock Split
The last split for RXi Pharma's took place on April 18, 2016. This was also 1 for 10 reverse split which for each 10 shares of the Company owned pre-split, the shareholder owned one share. This reduced the Company's issued and outstanding common stock from approximately 65.3 million shares to approximately 6.5 million shares. The reason for the stock split was also to increase the per share trading price of the Company's common stock to help ensure a share price high enough to satisfy the $1.00 per share minimum bid price requirement.
About RXi Pharmaceuticals Corp.
Founded in 2011, RXi Pharma is a clinical-stage company developing innovative therapeutics that address significant unmet medical needs. RXi developed a robust RNAi therapeutic platform including self-delivering RNA (sd-rxRNA®) compounds that have the ability to highly and selectively block the expression of any target in the genome, thus providing applicability to a broad spectrum of therapeutic areas. The Company is headquartered in Marlborough, Massachusetts.
Stock Performance Snapshot
January 08, 2018 - At Monday's closing bell, RXi Pharmaceuticals' stock dropped 3.80%, ending the trading session at $4.51.
Volume traded for the day: 50.20 thousand shares, which was above the 3-month average volume of 44.15 thousand shares.
After yesterday's close, RXi Pharmaceuticals' market cap was at $117.31 million.
The stock is part of the Healthcare sector, categorized under the Biotechnology industry.
Active-Investors (A-I) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and Canadian stocks. A-I has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles, and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
A-I has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third-party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email email@example.com. Rohit Tuli, a CFA® charter-holder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by A-I. A-I is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
A-I, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. A-I, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, A-I, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither A-I nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://active-investors.com/legal-disclaimer/.
For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:
Phone number: 73 29 92 6381
Office Address: 6, Jalan Kia Peng, Kuala Lumpur, 50450 Kuala Lumpur, Wilayah Persekutuan Kuala Lumpur, Malaysia
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.